Eisai To Further Strengthen Strategic Investment In Japan And The U.S.
This article was originally published in PharmAsia News
Executive Summary
At Eisai's third quarter earnings announcement meeting, President Haruo Naito stated that Eisai would further strength strategic investment in the U.S and Japan. Naito does not think that in the following 10 years, BRIC (Brazil, Russia, India and China) countries would have a drug market equal in size to the American market. He also does not believe the four countries would form a drug market cluster similar to the American one. Based on the predication, Eisai is going to set Japanese and American markets as its priorities, and will further invest in these markets to strength their foothold. Last December, Eisai announced its acquisition of U.S. biopharmaceutical company MGI Pharma for $3.9 billion dollars in cash. (Click here for more-Japanese language